JAMP Pharma

Your pharmacy’s generic partner.

We are committed to continuously improving the supply and access to affordable medicines for all Canadians.

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

Biosimilar drugs: BIOJAMP(MC) and Accessa join forces to simplify access to Simlandi(MC)

Boucherville, April 27th 2022 – BIOJAMPMC, the new biosimilars division of Canadian pharmaceutical company JAMP Pharma Group, is proud to partner with Accessa, an initiative of the Association québécoise des pharmaciens propriétaires, to facilitate access to SimlandiMC, which is used to treat certain inflammatory diseases affecting the joints, skin, digestive…
April 27, 2022
Press release
JAMP Pharma Launches SIMLANDI™, a NEW High-Concentration, Low Volume, Citrate-Free formulation, Biosimilar to Humira®, in Canada

SIMLANDI™ provides patients access to high-concentration, low volume, citrate-free formulations of adalimumab, in 40 mg/0.4 mL and 80 mg/0.8 mL presentations, not available in Canada before this week SIMLANDI™ is the first adalimumab biosimilar product launched by a Canadian-based company, JAMP Pharma Group The creation of BIOJAMP™ Pharma…
April 14, 2022
New launches, Press release
JAMP Pharma Group launches a new generic drug for the treatment of attention deficit hyperactivity disorder (ADHD)

JAMP Pharma Group, the Québec leader in prescription volume, launches Guanfacine XR, a niche generic that is equivalent to the reference product in size and appearance, offering an affordable alternative. JAMP Pharma Group is aligned with the provinces and insurers in their determination to significantly reduce prescription drug costs. In…
February 28, 2022
Press release

¹ Pharmaceutical manufacturers with the highest volume of prescriptions reported in Canada from January to August 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: CompuScript, January to August 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

² Pharmaceutical manufacturers with the highest volume of product launches in Canada from 2016 to 2021. Based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information service: Canadian Drug Store and Hospital Audit, moving annual total from January to December 2016 to 2021. All Rights Reserved. The statement expressed herein is not necessarily that of IQVIA Solutions Canada Inc. or any of its affiliated or subsidiary entities.

³ Proportion of complete orders delivered, Internal data Groupe JAMP Pharma, OTIF from January 1st 2021 to December 15th 2021.

JAMP Pharma

Proudly Canadian, we provide continuous access to high quality and affordable generic products: this is our promise.

Biosimilar drugs: BIOJAMP(MC) and Accessa join forces to simplify access to Simlandi(MC)

JAMP Pharma Launches SIMLANDI™, a NEW High-Concentration, Low Volume, Citrate-Free formulation, Biosimilar to Humira®, in Canada

JAMP Pharma Group launches a new generic drug for the treatment of attention deficit hyperactivity disorder (ADHD)